Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
Artificial intelligence technology has an established home in drug design for many developers. Now, researchers are seeing AI technology as a potential tool in driving therapeutic choices in the treatment of ovarian cancer.
The U.S. government’s toll-free substance abuse helpline, which provides free referral services to those looking for treatment, gets little publicity, a new study finds.
Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.
Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.
Two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.
UroGen Pharma announced positive top-line results from the New York based-company’s Phase III OLYMPUS clinical trial that evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer.
Pixium Vision announced that the bioelectronics company’s subretinal PRIMA system met the endpoints of the feasibility study, at interim 6 months follow-up after implantation and rehabilitation for patients with advanced dry age-related macular degeneration (AMD).
Sage Therapeutics’ postpartum depression oral treatment met the main goal of reducing the condition’s symptoms versus a placebo in a late-stage study, sending the drugmaker’s shares up 33 percent.